[Clinical evaluation of combination therapy with Fortimicin and Cefotax in the treatment of complicated urinary tract infections]

Clinical efficacy of combination therapy using Fortimicin (ASTM) and Cefotax (CTX) was studied in 63 patients with complicated urinary tract infections. The patients received 200 mg of ASTM i.m. and 1 g of CTX i.v. twice a day. The overall clinical efficacy of the treatment was evaluated by criteria proposed by the Japanese UTI Committee. The overall clinical efficacy rate was 68.3%. The rate was 67.3% in the patients with single bacterial infection and 72.7% in those with mixed infections. Subjective side effects were observed in one of the patients. Drug related aggravation in laboratory tests was observed in 8 items in 8 patients, but these were mild changes. We concluded that combination therapy with ASTM and CTX was useful for the treatment of complicated urinary tract infections.

[Clinical effect of prostaglandin F2 alpha on postoperative bowel movement in transurethral and transretroperitoneal urologic surgery]

The clinical effectiveness of prostaglandin F2 alpha (PGF2 alpha) injection on postoperative bowel movement was studied in 455 patients who underwent transurethral and transretroperitoneal operation. The patients were divided into two groups, 417 patients with PGF2 alpha injection and 38 without injection. 1,000 micrograms of PGF2 alpha were infused twice a day postoperatively until the onset of active flatus. The onset of flatus was recorded in each group. The onset of flatus after operation was 15 hours and 47 minutes for the injection group of 194 patients operated transurethrally, which was shorter than the 21 hours and 50 minutes for the uninjected group (p less than 0.01), but the onset of flatus was not significantly affected by the injection in the patients operated transretroperitoneally. Postoperative PGF2 alpha infusion facilitated flatus in the patients undergoing transretroperitoneal urologic surgery which took 1 and a half hours or more in doing so (p less than 0.05). Generally, postoperative paralytic ileus was milder after urological surgery than after bowel surgery, but PGF2 alpha injection was effective clinically both in transurethral surgery and transretroperitoneal surgery.

[Prophylactic and chemotherapeutic efficacy of pivmecillinam (PMPC) against infections after TUR-P and prostatectomy]

The prophylactic and chemotherapeutic efficacy of PMPC against infections after TUR-P has been investigated. Bacteriological evaluation: PMPC , 200-300 mg/day for 2-12 weeks, was administered to 49 patients, who had over 10(3)CFU/ml of microorganisms after CET or CEC treatment for 3-7 days. The eradication rate of microorganisms was 40.8% after 2 weeks, 52.2% after 4 weeks, 64.1% after 6 weeks, 65.0% after 8 weeks and 70.6% after 12 weeks. Effectiveness on pyuria : The improvement rate of pyuria against 59 patients who had over 10(5)/hpf of pyuria , was 15.3% after 2 weeks, 16.4% after 4 weeks, 25.4% after 6 weeks, 58.5% after 8 weeks, 72.7% after 10 weeks and 75.0% after 12 weeks. Overall clinical efficacy on PMPC was examined in 26 patients. The results of efficacy were 27.3% after 2 weeks, 48.0% after 4 weeks, 50.0% after 6 weeks, 69.2% after 8 weeks, 75.0% after 10 weeks and 77.0% after 12 weeks. The clinical response was evaluated according to a criterion for clinical evaluation of antimicrobial agent on chronic complicated UTI proposed by UTI committee in Japan. No severe adverse effect including allergic reaction was found. Following administration of PMPC , three patients experienced adverse gastric reactions, and drug administration was discontinued at week 6 or 8. PMPC was effective as a prophylactic chemotherapeutic drug against infections after TUR-P and prostatectomy.